Foundayo vs Zepbound: Pill or Weekly Shot?

Foundayo™ and Zepbound® are both Eli Lilly weight-loss medicines, but they are different drugs. Foundayo (orforglipron) is a once-daily GLP-1 pill the FDA approved on April 1, 2026. Zepbound (tirzepatide) is a once-weekly injection that acts on two hormone receptors, GIP and GLP-1. In separate 72-week trials, adults on the highest dose lost an average of 11.1% of their body weight on Foundayo and 20.9% on Zepbound, compared with 2.1% and 3.1% on placebo. No trial has compared them head to head. Foundayo costs less without insurance: $149 to $299 for 30 tablets at LillyDirect, versus $299 to $449 for a 28-day supply of Zepbound, as of November 2026.

So the choice is mostly pill or shot, and convenience or more weight loss. If you want tirzepatide itself at a lower cash price, compounded tirzepatide is a weekly injection that costs $120/mo flat at MaxLife. It is not FDA-approved, it is not Zepbound, and a licensed provider decides whether it's right for you.

Foundayo vs Zepbound at a Glance

Sources: the Foundayo label and Zepbound label on DailyMed, and LillyDirect, checked November 2026. Results come from separate trials.

Is Foundayo a Tirzepatide?

No. Foundayo contains orforglipron, not tirzepatide, and it is not a pill form of Zepbound or Mounjaro®. The two drugs differ in three ways:

• Different molecule. Orforglipron is a small, non-peptide molecule that the gut can absorb: in label testing, about 77% of a dose reached the bloodstream. Tirzepatide is a large peptide (4,813 daltons) that is not available as a pill, according to Lilly.
• Different targets. Foundayo activates only the GLP-1 receptor; the FDA describes it as a GLP-1 receptor partial agonist. Tirzepatide activates both GIP and GLP-1 receptors.
• Different schedule. Foundayo is taken every day. Zepbound is injected once a week.

Foundayo isn't semaglutide either, the medicine in Ozempic® and Wegovy®. As of November 2026, there is no FDA-approved tirzepatide pill, and drops or tablets sold online as "oral tirzepatide" are not approved. Our guide to the tirzepatide pill explains why.

Which Works Better for Weight Loss, Foundayo or Zepbound?

Zepbound produced about twice as much average weight loss in its main trial, but the two were tested in separate trials, not against each other. Both trials ran 72 weeks in adults with obesity, or overweight plus a weight-related condition, without diabetes, and both labels report everyone who was randomized:

Sources: Table 6 of the Foundayo label and the efficacy table of the Zepbound label. The trials were published in The New England Journal of Medicine (ATTAIN-1, SURMOUNT-1).

At lower doses, the gap stays: 7.4% (5.5 mg) and 8.3% (9 mg) on Foundayo, and 15.0% (5 mg) and 19.5% (10 mg) on Zepbound. In adults with type 2 diabetes, the top doses produced 9.6% (Foundayo) and 14.7% (Zepbound) average weight loss in their own trials.

So is Foundayo as effective as Zepbound? Not on average, based on what's published. Many people still lose meaningful weight on Foundayo: more than half of those on the top dose lost at least 10%. Zepbound has also beaten Wegovy head to head, 20.2% versus 13.7% in the SURMOUNT-5 trial. These results belong to Foundayo and Zepbound; they have not been shown for compounded tirzepatide.

Foundayo vs Zepbound Side Effects

Both drugs mainly cause stomach and bowel side effects, at similar rates, and both labels say these happen most while the dose is being raised.

Each column comes from that drug's own placebo-controlled trials, as listed in its FDA label, so the columns aren't a direct comparison.

Other differences worth knowing:

• Drug interactions. Foundayo is broken down by the liver enzyme CYP3A4. Its label caps the dose at 9 mg with strong CYP3A4 inhibitors, says to avoid strong inducers, and limits simvastatin to 20 mg a day when the two are used together. Tell your provider about every medicine you take.
• Birth control pills. Both labels advise switching to a non-oral method or adding a barrier method after starting and after each dose increase: for 30 days with Foundayo and 4 weeks with Zepbound.
• Shared warnings. Both carry a boxed warning about thyroid C-cell tumors, and neither should be used with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list pancreatitis, gallbladder problems, kidney problems from dehydration, and low blood sugar when used with insulin or a sulfonylurea.

Our tirzepatide side effects guide covers Zepbound's in more detail. Talk to your provider about any side effect that worries you.

How Do You Take Foundayo vs Zepbound?

Foundayo is one tablet a day, swallowed whole, at any time of day, with or without food or water. That is its main practical edge over the semaglutide pills, which must be taken on an empty stomach (see our Wegovy pill vs injection guide). According to the label, you start at 0.8 mg and step up at least every 30 days: 2.5 mg, then 5.5 mg, then 9 mg, 14.5 mg or 17.2 mg if needed and tolerated. If you miss a dose, take it as soon as possible, but never two in one day. After 7 or more missed doses in a row, the dose has to be built up again. Store it at room temperature.

Zepbound is one injection a week under the skin of the abdomen or thigh, or the back of the upper arm if someone else gives it. According to the label, you start at 2.5 mg for 4 weeks, then go up in 2.5 mg steps at least 4 weeks apart, to a maintenance dose of 5 mg, 10 mg or 15 mg. A missed dose can be taken within 4 days; after that, skip it. Store it in the refrigerator; single-dose pens and vials can stay unrefrigerated (up to 86°F) for up to 21 days in total, and the KwikPen has its own rules.

Foundayo also leaves the body faster, with a half-life of about 29 to 49 hours versus about 5 to 6 days for Zepbound. That is why it is taken every day and why its label has a restart rule after 7 or more missed doses. Your provider sets your dose and schedule.

Foundayo vs Zepbound Cost

Foundayo is cheaper without insurance. Here are LillyDirect's self-pay prices as of November 2026:

* Reduced prices through December 31, 2026; the regular prices are $199 (2.5 mg) and $299 (5.5 mg). † For Foundayo 14.5 mg and 17.2 mg and Zepbound 7.5 mg to 15 mg, when you refill within 45 days.

Sources: LillyDirect Foundayo and its terms, and LillyDirect Zepbound (vials or KwikPen), checked November 2026.

Watch the "month." LillyDirect's Zepbound month is 28 days, so a year takes 13 fills; a Foundayo month is 30 tablets, about 12 fills a year. At the top on-time prices, that works out to about $5,840 a year for Zepbound ($449 × 13 fills) and about $3,640 for Foundayo ($299 for every 30 days), by our math.

With insurance, either can cost much less. If your commercial plan covers it, Lilly's savings cards can bring either to as little as $25 a month (the Foundayo card runs through December 31, 2026). Eligible Medicare Part D members can get Foundayo or the Zepbound KwikPen for a $50 copay through the Medicare GLP-1 Bridge, which runs through December 31, 2027. For all tirzepatide prices by route, see our tirzepatide cost guide.

Can You Switch From Zepbound to Foundayo?

Yes, with your provider, and a 2026 trial gives a sense of what happens. In the Lilly-funded ATTAIN-MAINTAIN trial, adults whose weight loss on Zepbound had leveled off switched to Foundayo or to a placebo. After a year, the Foundayo group had kept 74.7% of the weight they had lost, compared with 49.2% on placebo. Lilly reported that the group regained about 5 kg (11 pounds) on average.

The trial had no group that stayed on Zepbound, so it can't show what switching costs compared with staying. A separate 2026 trial gives a hint: in SURMOUNT-MAINTAIN, people who stayed on their highest tolerated Zepbound dose for another year kept all of their prior weight loss on average, while those who dropped to 5 mg regained about 5.6 kg. Because these are different trials, the numbers aren't directly comparable.

A few rules apply either way:

• Never take them together. Both labels say not to combine them with another GLP-1 medicine.
• There's no official conversion between Zepbound doses and Foundayo doses. Your provider decides the starting dose.
• Going from Foundayo to Zepbound, the Zepbound label starts everyone at 2.5 mg for 4 weeks.

Sleep Apnea, Diabetes and Other Uses

Zepbound is the only one of the two approved for moderate to severe obstructive sleep apnea in adults with obesity. Our guide to Zepbound for sleep apnea explains that approval. Foundayo may follow: in the ATTAIN-OSA trials, published in JAMA on November 9, 2026, breathing pauses during sleep fell by about 17 to 18 an hour on Foundayo, versus about 5 on placebo, after a year. Lilly plans to ask the FDA for a sleep apnea approval by the end of 2026.

Neither Foundayo nor Zepbound is approved in the U.S. to treat type 2 diabetes (to lower blood sugar). The tirzepatide brand for diabetes is Mounjaro; see Zepbound vs Mounjaro. Lilly says Foundayo is approved for type 2 diabetes in some other countries.

Foundayo or Zepbound: Which Should You Choose?

Your provider will weigh your health, your other medicines and your coverage. In general:

Foundayo may fit you better if:

• you don't want injections, or needles have kept you from starting;
• you want a lower self-pay price at higher doses;
• you travel often and want a medicine stored at room temperature;
• you can take a pill every day without missing doses.

Zepbound may fit you better if:

• you want the larger average weight loss seen in trials;
• you have moderate to severe sleep apnea with obesity;
• your insurance covers it;
• you prefer one dose a week, or you take medicines that interact with Foundayo.

Is There a Lower-Cost Way to Get Tirzepatide?

Yes, if you're paying cash and your provider agrees it fits you. Compounded tirzepatide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. It is a weekly injection, like Zepbound, but it is not Zepbound, and the trial results above have not been shown for compounded tirzepatide. Our guide to tirzepatide vs Zepbound explains the differences.

Here is how MaxLife works. MaxLife is a telehealth patient management platform, not a pharmacy or drug maker. You complete an online intake in about 2 minutes. A licensed provider reviews your online intake, health history and clinical records, usually within 24 hours, can follow up with questions, and you can ask for a video visit. If the provider decides compounded tirzepatide is right for you, licensed partner pharmacies prepare and dispense it. The price is $120/mo flat, the same price at every dose, and it includes the provider's review and follow-up, the medicine if prescribed, supplies and free expedited shipping, with no membership fee. No insurance is needed, and HSA and FSA funds may be eligible. MaxLife doesn't sell pills, so if a daily pill is what you want, ask a provider about Foundayo or the Wegovy pill. See whether you qualify on the compounded tirzepatide page.

The Bottom Line

Foundayo is not a tirzepatide. It is a daily orforglipron pill with no food or water rules, and it costs less at LillyDirect. Zepbound is a weekly tirzepatide injection that produced about twice the average weight loss in its trials (20.9% versus 11.1% at the top doses, in separate studies) and is also approved for sleep apnea. If you'd rather not inject, Foundayo is a real option. If you want the most weight loss on average, Zepbound has the stronger data. If you want tirzepatide at a lower cash price, ask a licensed provider about compounded tirzepatide, which is not FDA-approved.